Hebei Kaiwei Hengcheng Pharmaceutical Co., Ltd.

In this study, the apixaban tablets (specification: 2.5 mg) developed by Hebei Kaiwei Hengcheng Pharmaceutical Co., Ltd. were used as the test preparation, and the apixaban tablets (trade name: Eliquis®; specification: 2.5 mg) certified by BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCHINSTITUTE were used as the reference preparation to evaluate the bioequivalence of the test preparation and the reference preparation under fasting and fed conditions.

Primary objective: To evaluate the dose-effect relationship of topiramate tablets in the treatment of gout with hyperuricemia. Secondary objective: To evaluate the efficacy and safety of topiramate tablets in the treatment of gout with hyperuricemia compared with allopurinol tablets.

Primary study objective: To verify the efficacy of the Phase III recommended dose of topiramate tablets in treating gout with hyperuricemia compared to allopurinol 300 mg; Secondary study objective: To evaluate the safety and tolerability of the Phase III recommended dose of topiramate tablets in treating gout with hyperuricemia compared to allopurinol 300 mg.